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64E4NSTAhmmific Alma and Research Goals. 
The primary goal of this research is to develop a synthetic elastase inhibitor 
which would be useful for the treatment of human emphysema. A variety of structures 
are being investigated including heterocyclic mechanism-based inhibitors and peptide 
transition state analogs. All of the inhibitors are being tested for specificity 
with other cellular proteases such as cathepsin G and the mast cell chymotrypsin-
like enzymes (chymases). A secondary goal of this research is the extension of any 
potent inhibitor structures to cathepsin G and mast cell chymases. Any promising 
elastase inhibitors will be provided to other investigators for studies in animal 
models of emphysema. This research should lead to a better understanding of the 
active site structures of the serine proteases involved in connective tissue 
turnover, may produce clinically useful drugs for the treatment of emphysema and 
related diseases, is stimulating the research of medicinal chemists in 
pharmaceutical companies, and will provide new tools for the in vivo and in vitro  
study of the role of leukocyte and mast cell proteases in variety of physiological 
processes. 
2.Research Report. 
Active Site Structure and Molecular Modeling. Molecular modeling is 
one technology which is rapidly improving and becoming quite useful to the 
biochemist for the process of inhibitor design. A necessary starting point is an x-
ray crystal structure of the target protease or a close relative. X-ray structures 
are now available for porcine pancreatic elastase and human neutrophil elastase. In 
addition, an increasing number of small molecule inhibitor complexes with serine 
proteases are becoming available. 
The primary specificity pocket (S1), in particular, is a major determinate of 
serine protease specificity and is most often utilized in inhibitor design. This 
pocket is a bumpy hydrophobic space in most serine proteases with a variety of amino 
acid side chains forming the surface of the pocket. The primary substrate binding 
subsite takes on a different size and shape in individual serine proteases due to 
sequence differences in this region of serine proteases. 
The two neutrophil proteases (HL elastase and cathepsin G) have a long narrow 
S1 pocket with carboxyl groups at the very end. In the case of HL elastase, Asp-226 
points toward the interior of the protein into a region which has several water 
molecules trapped in the elastase structure. The front of the pocket is very narrow 
and hydrophobic. A similar situation occurs with cathepsin G where residue 226 is a 
glutamic acid residue. Construction of a cathepsin G model using the rat mast cell 
protease II backbone indicates that this Glu-226 would be placed in a similar 
environment to Asp-226 in HL elastase. 
Previous studies with synthetic peptide thiobenzyl esters have shown that 
cathepsin G and RMCP II prefer substrates with a P1 Phe, while HL and porcine 
pancreatic (PP) elastase most effectively hydrolyzed a norvaline containing 
substrate. 	Interestingly inhibitors with long hydrocarbon or fluorocarbon chains 
which can interact with this hydrophobic S1 pocket are often the most effective HL 
elastase inhibitors. 
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